Hepatitis Monthly

Published by: Kowsar

Serum Levels of Anti-Hepatitis B Surface Antibody Among Vaccinated Population Aged 1 to 18 Years in Ahvaz City Southwest of Iran

Reza Norouzirad 1 , Abdol Hussein Shakurnia 2 , * , Mohammad-Ali Assarehzadegan 3 , Amirarsalan Serajian 4 and Mehdi Khabazkhoob 5
Authors Information
1 Biochemistry Department, Faculty of Medicine, Dezful University of Medical Sciences, Dezful, IR Iran
2 Health Research Institue, Infectious and Tropical Diseases Research Center, Immunology Department, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Immunology Department, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
4 Health Education Research Group, Jahade Daneshgahi of Khouzestan, Ahvaz, IR Iran
5 Epidemiology Department, Faculty of Health, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: January 2014, 14 (1); e13625
  • Published Online: January 12, 2014
  • Article Type: Research Article
  • Received: July 16, 2013
  • Revised: September 8, 2013
  • Accepted: November 17, 2013
  • DOI: 10.5812/hepatmon.13625

To Cite: Norouzirad R, Shakurnia A H, Assarehzadegan M, Serajian A, Khabazkhoob M. et al. Serum Levels of Anti-Hepatitis B Surface Antibody Among Vaccinated Population Aged 1 to 18 Years in Ahvaz City Southwest of Iran, Hepat Mon. 2014 ;14(1):e13625. doi: 10.5812/hepatmon.13625.

Copyright: Copyright © 2014, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. su FH, Chen JD, Cheng SH, Sung KY, Jeng JJ, Chu FY. Waning-off effect of serum hepatitis B surface antibody amongst Taiwanese university students: 18 years post-implementation of Taiwan's national hepatitis B vaccination programme. J Viral Hepat. 2008; 15(1): 14-9[DOI][PubMed]
  • 2. Livramento Ad, Cordova CM, Scaraveli NG, Tonial GC, Spada C, Treitinger A. Anti-HBs levels among children and adolescents with complete immunization schedule against hepatitis B virus. A cross-sectional study in Blumenau, State of Santa Catarina, Brazil, 2007-2008. Rev Soc Bras Med Trop. 2011; 44(4): 412-5[PubMed]
  • 3. Ansari-Moghaddam A, Ostovaneh MR, Sharifi Mood B, Sanei-Moghaddam E, Modabbernia A, Poustchi H. Seroprevalence of hepatitis B surface antigen and anti hepatitis C antibody in zahedan city, iran: a population-based study. Hepat Mon. 2012; 12(9)[DOI][PubMed]
  • 4. Abedi F, Madani H, Asadi A, Nejatizadeh A. Significance of blood-related high-risk behaviors and horizontal transmission of hepatitis B virus in Iran. Arch Virol. 2011; 156(4): 629-35[DOI][PubMed]
  • 5. Alavian SM, Fallahian F, Lankarani KB. The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis. 2007; 16(4): 403-6[PubMed]
  • 6. Merat S, Rezvan H, Nouraie M, Jamali A, Assari S, Abolghasemi H, et al. The prevalence of hepatitis B surface antigen and anti-hepatitis B core antibody in Iran: a population-based study. Arch Iran Med. 2009; 12(3): 225-31[PubMed]
  • 7. Chen DS. Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. J Hepatol. 2009; 50(4): 805-16[DOI][PubMed]
  • 8. Esteghamati A, Keshtkar AA, Nadjafi L, Gouya MM, Salaramoli M, Roshandel G, et al. Hepatitis B vaccination coverage among Iranian children aged 15-26 months in 2006. East Mediterr Health J. 2011; 17(2): 93-100[PubMed]
  • 9. Fathimoghaddam F, Hedayati-Moghaddam MR, Bidkhori HR, Ahmadi S, Sima HR. The prevalence of hepatitis B antigen-positivity in the general population of Mashhad, Iran. Hepat Mon. 2011; 11(5): 346-50[PubMed]
  • 10. Baghianimoghadam MH, Shadkam MN, Hadinedoushan H. Immunity to hepatitis B vaccine among health care workers. Vaccine. 2011; 29(15): 2727-9[DOI][PubMed]
  • 11. Alavian SM, Gooya MM, Hajarizadeh B, Esteghamati AR, Moeinzadeh AM, Haghazali M, et al. Mass Vaccination Campaign against Hepatitis B in Adolescents in Iran: Estimating Coverage using Administrative Data. Hepat Mon. 2009; 9(3): 189-95
  • 12. Hassan S, Ziba F. Antibody titer in Iranian children 6 years after hepatitis B vaccine administration. Vaccine. 2007; 25(17): 3511-4[DOI][PubMed]
  • 13. Alavian SM, Fallahian F, Lankarani KB. Implementing strategies for hepatitis B vaccination. Saudi J Kidney Dis Transpl. 2010; 21(1): 10-22[PubMed]
  • 14. Da Villa G, Romano L, Sepe A, Iorio R, Paribello N, Zappa A, et al. Impact of hepatitis B vaccination in a highly endemic area of south Italy and long-term duration of anti-HBs antibody in two cohorts of vaccinated individuals. Vaccine. 2007; 25(16): 3133-6[DOI][PubMed]
  • 15. Alavian SM, Mansouri S, Abouzari M, Assari S, Bonab MS, Miri SM. Long-term efficacy of hepatitis B vaccination in healthcare workers of Oil Company Hospital, Tehran, Iran (1989-2005). Eur J Gastroenterol Hepatol. 2008; 20(2): 131-4[DOI][PubMed]
  • 16. Zhang H, Li Q, Sun J, Wang C, Gu Q, Feng X, et al. Seroprevalence and risk factors for hepatitis B infection in an adult population in Northeast China. Int J Med Sci. 2011; 8(4): 321-31[PubMed]
  • 17. Floreani A, Baldo V, Cristofoletti M, Renzulli G, Valeri A, Zanetti C, et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine. 2004; 22(5-6): 607-10[PubMed]
  • 18. Aghakhani A, Banifazl M, Izadi N, McFarland W, Sofian M, Khadem-Sadegh A, et al. Persistence of antibody to hepatitis B surface antigen among vaccinated children in a low hepatitis B virus endemic area. World J Pediatr. 2011; 7(4): 358-60[DOI][PubMed]
  • 19. Afifi SS, Mahran MH, Said ZN, Salama II, El Khayat H. Serum Level of Anti-hepatitis B Surface Antigen among Newborns and Fully Vaccinated Infants and Children Aged 6 to 11 Years. Aust J Basic Applied Sci. 2009; 3(4): 3239-45
  • 20. Jafarzadeh A, Montazerifar SJ. Persistence of anti-HBs antibody and immunological memory in children vaccinated with hepatitis B vaccine at birth. J Ayub Med Coll Abbottabad. 2006; 18(4): 4-9[PubMed]
  • 21. Shamsizadeh A, Makvandi M, Shoshtari G. Prevalence of anti hepatitis B surface antibody among children in Ahvaz, Iran, five years after vaccination. J J Microbiol. 2011; 4(1): 49-54
  • 22. Javad Hosseini SM, Ranjbar R, Abolghasemi H, Turkaman M. Evaluation of the Level of HBV Antibody Titer after HBV Vaccination among Children in Tehran, Iran. Hepat Mon. 2009; 9(2): 150-3
  • 23. Bialek SR, Bower WA, Novak R, Helgenberger L, Auerbach SB, Williams IT, et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J. 2008; 27(10): 881-5[DOI][PubMed]
  • 24. Alfaleh F, Alshehri S, Alansari S, Aljeffri M, Almazrou Y, Shaffi A, et al. Long-term protection of hepatitis B vaccine 18 years after vaccination. J Infect. 2008; 57(5): 404-9[DOI][PubMed]
  • 25. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005; 142(5): 333-41[PubMed]
  • 26. But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine. 2008; 26(51): 6587-91[DOI][PubMed]
  • 27. Lin YC, Chang MH, Ni YH, Hsu HY, Chen DS. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis. 2003; 187(1): 134-8[DOI][PubMed]
  • 28. Schonberger K, Riedel C, Ruckinger S, Mansmann U, Jilg W, Kries RV. Determinants of Long-term protection after hepatitis B vaccination in infancy: a meta-analysis. Pediatr Infect Dis J. 2013; 32(4): 307-13[DOI][PubMed]
  • 29. Mackie CO, Buxton JA, Tadwalkar S, Patrick DM. Hepatitis B immunization strategies: timing is everything. CMAJ. 2009; 180(2): 196-202[DOI][PubMed]
  • 30. Su FH, Cheng SH, Li CY, Chen JD, Hsiao CY, Chien CC, et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine. 2007; 25(47): 8085-90[DOI][PubMed]
  • 31. Lu CY, Chiang BL, Chi WK, Chang MH, Ni YH, Hsu HM, et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology. 2004; 40(6): 1415-20[DOI][PubMed]
  • 32. Yuen MF, Lim WL, Chan AO, Wong DK, Sum SS, Lai CL. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol. 2004; 2(10): 941-5[PubMed]
  • 33. Chen DS. Long-term protection of hepatitis B vaccine: lessons from Alaskan experience after 15 years. Ann Intern Med. 2005; 142(5): 384-5[PubMed]
  • 34. Shaaban FA, Hassanin AI, Samy SM, Salama SI, Said ZN. Long-term immunity to hepatitis B among a sample of fully vaccinated children in Cairo, Egypt. East Mediterr Health J. 2007; 13(4): 750-7[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader